You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 144 No. 10, October 1984 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL INVESTIGATIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Insulin Pump Therapy Improves Blood Glucose Control During Hyperalimentation

Michael Bergman, MD; Sunita RaviKumar, MD; Carolyn Auerhahn, RN, MS; Nancy DelSavio, RD; John Savino, MD; Philip Felig, MD

Arch Intern Med. 1984;144(10):2013-2015.


Abstract



• The present study investigated the feasibility of basal continuous subcutaneous insulin infusion (CSII) in four patients with postoperative sepsis or extensive burns during continuous enteral hyperalimentation with 2,500 to 3,000 calories/day, containing approximately 390 g of simple carbohydrates. The mean duration of CSII treatment was 16.8 days (range, seven to 32 days). The mean capillary blood glucose level fell from 322±52 mg/dL during pre-CSII therapy to 195± 33 mg/dL during CSII therapy. Only 1.3% of 1,254 capillary blood glucose values were less than 60 mg/dL. Most values (61.6%) were between 61 and 200 mg/dL. The mean insulin infusion rate was 2.5±1.5 units/hr. These preliminary observations suggest that basal infusion CSII is a safe and effective means of improving blood glucose control In patients receiving enteral hyperalimentation despite the high glucose intake and presence of insulin resistance. Thus, CSII therapy can enhance the metabolic response to hyperalimentation without requiring an intravenous access route.

(Arch Intern Med 1984;144:2013-2015)



Author Affiliations



From the Department of Medicine, Rachmiel Levine Diabetes Center, New York Medical College, Valhalla, NY (Drs Bergman, RaviKumar, and Savino, and Mss Auerhahn and DelSavio); and the Department of Internal Medicine, Division of Endocrinology and Metabolism, Yale University School of Medicine, New Haven, Conn (Dr Felig).


Footnotes



Accepted for publication Feb 29, 1984.

Reprint requests to New York Medical College, Department of Medicine, Rachmiel Levine Diabetes Center, Valhalla, NY 10595 (Dr Bergman).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Questions and Answers
JAMA 1989;262:1239-1243.
 





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.